Discontinuation of Primary and SecondaryToxoplasma gondiiProphylaxis Is Safe in HIV‐Infected Patients after Immunological Restoration with Highly Active Antiretroviral Therapy: Results of an Open, Randomized, Multicenter Clinical Trial | Zendy

José M. Miró | Zendy; Juan Carlos López | Zendy; Daniel Podzamczer | Zendy; José M. Peña | Zendy; J. Alberdi | Zendy; Estebán Martínez | Zendy; Peré Domingo | Zendy; Jaime Cosín | Zendy; Xavier Claramonte | Zendy; José Ramón Arribas | Zendy; Miguel Santín | Zendy; Esteban Ribera | Zendy

Open Access

Discontinuation of Primary and SecondaryToxoplasma gondiiProphylaxis Is Safe in HIV‐Infected Patients after Immunological Restoration with Highly Active Antiretroviral Therapy: Results of an Open, Randomized, Multicenter Clinical Trial

Author(s) -

José M. Miró,

Juan Carlos López,

Daniel Podzamczer,

José M. Peña,

J. Alberdi,

Estebán Martínez,

Peré Domingo,

Jaime Cosín,

Xavier Claramonte,

José Ramón Arribas,

Miguel Santín,

Esteban Ribera

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/504872

Subject(s) - medicine , discontinuation , randomized controlled trial , confidence interval , clinical trial , chemoprophylaxis , surgery

To our knowledge, no randomized trials have evaluated whether prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count increases in response to highly active antiretroviral therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research